MedPath
Found 7 clinical trials|View Analysis
Sort by:

Enhancing Thoracolumbar Burst Fracture Treatment

Completed
Conditions
Surgery
Interventions
Device: Free-hand
Device: Robot-assisted
First Posted Date
2024-08-20
Last Posted Date
2024-08-20
Lead Sponsor
Peng Liu
Target Recruit Count
182
Registration Number
NCT06561997
Locations
🇨🇳

"Tianji" 3rd generation orthopedic robot, Chengdu, Sichuan, China

Improved Pain Management in Knee Osteoarthritis-related Surgeries

Completed
Conditions
Pain Management
Knee Osteoarthritis
High Tibial Osteotomy
Unicompartmental Knee Arthroplasty
Total Knee Arthroplasty
Interventions
Procedure: Preoperative pain managment
Procedure: Intraoperative pain managment
Procedure: Postoperative pain managment
First Posted Date
2023-11-09
Last Posted Date
2023-11-09
Lead Sponsor
Peng Liu
Target Recruit Count
714
Registration Number
NCT06124170
Locations
🇨🇳

Sichuan Provincial People's Hospital, Chengdu, Sichuan, China

Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma

Phase 2
Recruiting
Conditions
Diffuse Large B Cell Lymphoma
Interventions
Drug: Zanubrutinib, Polatuzumab Vedotin, Rituximab
First Posted Date
2023-07-11
Last Posted Date
2023-07-11
Lead Sponsor
Peng Liu
Target Recruit Count
30
Registration Number
NCT05940064
Locations
🇨🇳

Zhongshan Hospital,Fudan University, Shanghai, Shanghai, China

Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2
Recruiting
Conditions
Diffuse Large B Cell Lymphoma
Interventions
Drug: Zanubrutinib, Polatuzumab vedotin and Rituximab
First Posted Date
2023-07-11
Last Posted Date
2023-07-11
Lead Sponsor
Peng Liu
Target Recruit Count
35
Registration Number
NCT05940051
Locations
🇨🇳

Zhongshan Hospital,Fudan University, Shanghai, Shanghai, China

The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.

Phase 2
Not yet recruiting
Conditions
Histological or Cytological Confirmed Stage Ⅲ and Ⅳa Thymoma
Interventions
First Posted Date
2023-04-18
Last Posted Date
2023-04-18
Lead Sponsor
Peng Liu
Target Recruit Count
50
Registration Number
NCT05816694
Locations
🇨🇳

Yian Zhang, Shanghai, Shanghai, China

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

Phase 1
Conditions
Multiple Myeloma in Relapse
Multiple Myeloma Progression
Interventions
Biological: anti-CD19/BCMA CAR-T cells
Drug: Fludarabine
Drug: Cyclophosphamide
First Posted Date
2018-10-16
Last Posted Date
2018-10-16
Lead Sponsor
Peng Liu
Target Recruit Count
20
Registration Number
NCT03706547
Locations
🇨🇳

Department of Hematology ,Fudan University Zhongshan Hospital, Shanghai, China

Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM

Phase 2
Conditions
Multiple Myeloma
Interventions
First Posted Date
2018-07-30
Last Posted Date
2018-07-30
Lead Sponsor
Peng Liu
Target Recruit Count
25
Registration Number
NCT03605056
Locations
🇨🇳

180 Fenglin Road, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath